Boston Scientific Corporation Is Expensive But Worth It
Boston Scientific is a 'forever stock' due to management foresight, robust R&D, and leadership in AI-driven medical devices. Despite a weak valuation grade, its strong financials, global expansion,...
Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q2 2025 Earnings Conference Call July 23, 2025 8:00 AM ET Company Participants Jonathan R. Monson - Executive VP & CFO Kenneth M.
Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared du...
Boston Scientific (BSX) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Boston Scientific (BSX) closed at $102.41, indicating a -1.37% shift from the previous trading day.
Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report?
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Boston Scientific Climbs 40.5% in a Year: What's Driving the Stock?
BSX rallies 40.5% in a year, fueled by WATCHMAN growth, MedSurg gains, acquisitions and global expansion efforts.
BSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?
Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). ...
Boston Scientific (BSX) Surpasses Market Returns: Some Facts Worth Knowing
Boston Scientific (BSX) concluded the recent trading session at $102.36, signifying a +1.05% move from its prior day's close.
Boston Scientific: Old, Reliable; Buy For Their Consistent Growth
Boston Scientific is a global leader in medical devices, excelling in both MedSurg and Cardiovascular segments with consistent, industry-beating growth. Q1 2024 was a record quarter, with 21% YoY r...
Boston Scientific Corporation (BSX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX ) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 8:01 AM ET Company Participants Michael Mahoney - Chairman and Chief Executive Offic...
Boston Scientific to not seek US approval for heart device amid regulatory challenges
Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.
Here is Why Growth Investors Should Buy Boston Scientific (BSX) Now
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Here is how Boston Scientific (BSX) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints
Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO , April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ...
Related Companies